Biogen Is ‘Evaluating Strategic Options’ For Its Biosimilars Business

CEO Says ‘Formal Process Is Underway’ To Consider Selling To A New Owner

Biogen revealed that a formal process is now underway to “evaluate strategic options” for its biosimilars business, pointing to a potential transfer of the unit to a new owner.

Sell decision - yes or no? Wooden blocks
Biogen is weighing whether to sell its biosimilars business • Source: Shutterstock

Biogen is considering selling its biosimilars business to a new owner, as part of a strategic review of the unit that has been formally kicked off by the former Samsung Bioepis joint venture partner.

While Biogen in early 2022 agreed to sell its stake in Samsung Bioepis to partner Samsung Biologics (see sidebar) –...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

More from Products

Bio-Thera Matches Alvotech With US Golimumab Filing Acceptance

 
• By 

Bio-Thera is one step closer to launching a biosimilar to Johnson & Johnson’s Simponi in the US, following FDA acceptance of its BAT2506 proposed golimumab candidate.

Samsung Bioepis Finds New US Partner For Ophthalmic Biosimilars

 
• By 

Samsung Bioepis has announced a fresh ophthalmic biosimilars partnership with Harrow, as the end approaches for a longstanding US commercialization alliance with Biogen on the Korean firm's Lucentis (ranibizumab) and Eylea (aflibercept) rivals Byooviz and Opuviz.

‘Our Position Has Naturally Shifted’ – How Standalone Sandoz Is Taking On Originator Abuses

 
• By 

As a standalone generics and biosimilars company, Sandoz now feels freer to speak out against originator abuses of intellectual property, the firm’s global IP head Julia Pike tells Generics Bulletin, including challenges to Bayer on rivaroxaban and Amgen on etanercept.